$REGN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in REGENERON PHARMACEUTICALS, INC.. Get notifications about new insider transactions in REGENERON PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 3 4 5 6 7 8 9 10 11 ... 48 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 485.63 | 62 | 30,109 | 26,186 | 26.2 K to 26.2 K (-0.24 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 491.72 | 85 | 41,796 | 25,507 | 25.6 K to 25.5 K (-0.33 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.96 | 22 | 10,669 | 26,248 | 26.3 K to 26.2 K (-0.08 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.11 | 51 | 24,996 | 25,592 | 25.6 K to 25.6 K (-0.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 483.51 | 139 | 67,208 | 26,270 | 26.4 K to 26.3 K (-0.53 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.39 | 128 | 62,642 | 25,643 | 25.8 K to 25.6 K (-0.50 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 492.05 | 2,317 | 1,140,080 | 26,409 | 28.7 K to 26.4 K (-8.07 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.55 | 246 | 120,183 | 25,771 | 26 K to 25.8 K (-0.95 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,000 | 818,100 | 28,726 | 25.7 K to 28.7 K (+11.66 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 487.29 | 91 | 44,343 | 26,017 | 26.1 K to 26 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.20 | 1,162 | 567,288 | 25,726 | 26.9 K to 25.7 K (-4.32 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.66 | 78 | 37,959 | 26,108 | 26.2 K to 26.1 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,500 | 409,050 | 26,888 | 25.4 K to 26.9 K (+5.91 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 485.63 | 62 | 30,109 | 26,186 | 26.2 K to 26.2 K (-0.24 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,549 | 756,253 | 25,388 | 26.9 K to 25.4 K (-5.75 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.96 | 22 | 10,669 | 26,248 | 26.3 K to 26.2 K (-0.08 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,000 | 545,400 | 26,937 | 24.9 K to 26.9 K (+8.02 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 483.51 | 139 | 67,208 | 26,270 | 26.4 K to 26.3 K (-0.53 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,936 | 945,194 | 24,937 | 26.9 K to 24.9 K (-7.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 492.05 | 2,317 | 1,140,080 | 26,409 | 28.7 K to 26.4 K (-8.07 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,500 | 681,750 | 26,873 | 24.4 K to 26.9 K (+10.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,000 | 818,100 | 28,726 | 25.7 K to 28.7 K (+11.66 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.08 | 156 | 76,920 | 24,373 | 24.5 K to 24.4 K (-0.64 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.20 | 1,162 | 567,288 | 25,726 | 26.9 K to 25.7 K (-4.32 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.61 | 64 | 31,527 | 24,529 | 24.6 K to 24.5 K (-0.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,500 | 409,050 | 26,888 | 25.4 K to 26.9 K (+5.91 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.70 | 87 | 42,691 | 24,593 | 24.7 K to 24.6 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,549 | 756,253 | 25,388 | 26.9 K to 25.4 K (-5.75 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.46 | 61 | 29,857 | 24,680 | 24.7 K to 24.7 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,000 | 545,400 | 26,937 | 24.9 K to 26.9 K (+8.02 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.77 | 23 | 11,242 | 24,741 | 24.8 K to 24.7 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,936 | 945,194 | 24,937 | 26.9 K to 24.9 K (-7.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.27 | 23 | 11,184 | 24,764 | 24.8 K to 24.8 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,500 | 681,750 | 26,873 | 24.4 K to 26.9 K (+10.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.14 | 1 | 484 | 24,787 | 24.8 K to 24.8 K (0.00 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.08 | 156 | 76,920 | 24,373 | 24.5 K to 24.4 K (-0.64 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 481.91 | 87 | 41,926 | 24,788 | 24.9 K to 24.8 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.61 | 64 | 31,527 | 24,529 | 24.6 K to 24.5 K (-0.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 479.50 | 75 | 35,963 | 24,875 | 25 K to 24.9 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.70 | 87 | 42,691 | 24,593 | 24.7 K to 24.6 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 478.97 | 23 | 11,016 | 24,950 | 25 K to 25 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.46 | 61 | 29,857 | 24,680 | 24.7 K to 24.7 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.77 | 23 | 11,242 | 24,741 | 24.8 K to 24.7 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.27 | 23 | 11,184 | 24,764 | 24.8 K to 24.8 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.14 | 1 | 484 | 24,787 | 24.8 K to 24.8 K (0.00 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 481.91 | 87 | 41,926 | 24,788 | 24.9 K to 24.8 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 479.50 | 75 | 35,963 | 24,875 | 25 K to 24.9 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 478.97 | 23 | 11,016 | 24,950 | 25 K to 25 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 39,933 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 44,933 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 49,933 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 497.32 | 100 | 49,732 | 14,438 | 14.5 K to 14.4 K (-0.69 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 496.50 | 210 | 104,265 | 14,538 | 14.7 K to 14.5 K (-1.42 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 495.19 | 321 | 158,956 | 14,748 | 15.1 K to 14.7 K (-2.13 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 494.36 | 111 | 54,874 | 15,069 | 15.2 K to 15.1 K (-0.73 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 493.35 | 652 | 321,664 | 15,180 | 15.8 K to 15.2 K (-4.12 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 492.62 | 521 | 256,655 | 15,832 | 16.4 K to 15.8 K (-3.19 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 491.42 | 450 | 221,139 | 16,353 | 16.8 K to 16.4 K (-2.68 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 490.32 | 484 | 237,315 | 16,803 | 17.3 K to 16.8 K (-2.80 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 489.72 | 734 | 359,454 | 17,287 | 18 K to 17.3 K (-4.07 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 488.26 | 1,626 | 793,911 | 18,021 | 19.6 K to 18 K (-8.28 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 487.71 | 470 | 229,224 | 19,647 | 20.1 K to 19.6 K (-2.34 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 486.61 | 485 | 236,006 | 20,117 | 20.6 K to 20.1 K (-2.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 485.65 | 441 | 214,172 | 20,602 | 21 K to 20.6 K (-2.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 484.58 | 192 | 93,039 | 21,043 | 21.2 K to 21 K (-0.90 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 488.22 | 2,689 | 1,312,824 | 21,235 | 23.9 K to 21.2 K (-11.24 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 23,924 | 18.9 K to 23.9 K (+26.42 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 488.22 | 2,757 | 1,346,023 | 18,924 | 21.7 K to 18.9 K (-12.72 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 21,681 | 16.7 K to 21.7 K (+29.97 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 488.22 | 2,757 | 1,346,023 | 16,681 | 19.4 K to 16.7 K (-14.18 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 19,438 | 14.4 K to 19.4 K (+34.63 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 495.66 | 1 | 496 | 28,943 | 28.9 K to 28.9 K (0.00 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 493.35 | 1 | 493 | 28,944 | 28.9 K to 28.9 K (0.00 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 492.71 | 3 | 1,478 | 28,945 | 28.9 K to 28.9 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 491.13 | 2 | 982 | 28,948 | 29 K to 28.9 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 490.35 | 1 | 490 | 28,950 | 29 K to 29 K (0.00 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 489.56 | 5 | 2,448 | 28,951 | 29 K to 29 K (-0.02 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 488.62 | 10 | 4,886 | 28,956 | 29 K to 29 K (-0.03 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 487.54 | 1 | 488 | 28,966 | 29 K to 29 K (0.00 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 486.53 | 4 | 1,946 | 28,967 | 29 K to 29 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 485.65 | 3 | 1,457 | 28,971 | 29 K to 29 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 484.54 | 8 | 3,876 | 28,974 | 29 K to 29 K (-0.03 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 483.49 | 11 | 5,318 | 28,982 | 29 K to 29 K (-0.04 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 482.43 | 14 | 6,754 | 28,993 | 29 K to 29 K (-0.05 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 481.34 | 4 | 1,925 | 29,007 | 29 K to 29 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 480.55 | 8 | 3,844 | 29,011 | 29 K to 29 K (-0.03 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 479.60 | 18 | 8,633 | 29,019 | 29 K to 29 K (-0.06 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 478.45 | 4 | 1,914 | 29,037 | 29 K to 29 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 477.58 | 2 | 955 | 29,041 | 29 K to 29 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 469.49 | 4 | 1,878 | 29,043 | 29 K to 29 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 468.14 | 24 | 11,235 | 29,047 | 29.1 K to 29 K (-0.08 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 467.51 | 19 | 8,883 | 29,071 | 29.1 K to 29.1 K (-0.07 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 466.60 | 23 | 10,732 | 29,090 | 29.1 K to 29.1 K (-0.08 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 465.35 | 16 | 7,446 | 29,113 | 29.1 K to 29.1 K (-0.05 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 464.49 | 9 | 4,180 | 29,129 | 29.1 K to 29.1 K (-0.03 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 463.16 | 3 | 1,389 | 29,138 | 29.1 K to 29.1 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 462.80 | 2 | 926 | 29,141 | 29.1 K to 29.1 K (-0.01 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | Sanofi | Sell | S | 489.65 | 128,914 | 63,123,153 | 20,421,899 | 20.6 M to 20.4 M (-0.63 %) | |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Option Exercise | M | 30.63 | 150,000 | 4,594,500 | 0 | |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Option Exercise | M | 30.63 | 96,736 | 2,963,024 | 150,000 | |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 486.31 | 7 | 3,404 | 517,799 | 517.8 K to 517.8 K (0.00 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 485.63 | 1,693 | 822,172 | 517,806 | 519.5 K to 517.8 K (-0.33 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 484.72 | 345 | 167,228 | 519,499 | 519.8 K to 519.5 K (-0.07 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 483.80 | 355 | 171,749 | 519,844 | 520.2 K to 519.8 K (-0.07 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 481.68 | 100 | 48,168 | 520,199 | 520.3 K to 520.2 K (-0.02 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 480.34 | 60 | 28,820 | 520,299 | 520.4 K to 520.3 K (-0.01 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 479.60 | 1,651 | 791,820 | 520,359 | 522 K to 520.4 K (-0.32 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 478.43 | 1,469 | 702,814 | 522,010 | 523.5 K to 522 K (-0.28 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 477.50 | 4,735 | 2,260,963 | 523,479 | 528.2 K to 523.5 K (-0.90 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 476.51 | 7,197 | 3,429,442 | 528,214 | 535.4 K to 528.2 K (-1.34 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 475.43 | 4,223 | 2,007,741 | 535,411 | 539.6 K to 535.4 K (-0.78 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 474.52 | 7,060 | 3,350,111 | 539,634 | 546.7 K to 539.6 K (-1.29 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 473.39 | 8,024 | 3,798,481 | 546,694 | 554.7 K to 546.7 K (-1.45 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 472.56 | 10,270 | 4,853,191 | 554,718 | 565 K to 554.7 K (-1.82 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 471.34 | 5,258 | 2,478,306 | 564,988 | 570.2 K to 565 K (-0.92 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 470.48 | 5,531 | 2,602,225 | 570,246 | 575.8 K to 570.2 K (-0.96 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 469.46 | 7,250 | 3,403,585 | 575,777 | 583 K to 575.8 K (-1.24 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 468.49 | 8,542 | 4,001,842 | 583,027 | 591.6 K to 583 K (-1.44 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 467.53 | 10,023 | 4,686,053 | 591,569 | 601.6 K to 591.6 K (-1.67 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 466.58 | 11,916 | 5,559,767 | 601,592 | 613.5 K to 601.6 K (-1.94 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 465.45 | 7,068 | 3,289,801 | 613,508 | 620.6 K to 613.5 K (-1.14 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 464.59 | 5,099 | 2,368,944 | 620,576 | 625.7 K to 620.6 K (-0.81 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 463.54 | 5,463 | 2,532,319 | 625,675 | 631.1 K to 625.7 K (-0.87 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 462.43 | 3,317 | 1,533,880 | 631,138 | 634.5 K to 631.1 K (-0.52 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Sell | S | 461.79 | 1,159 | 535,215 | 634,455 | 635.6 K to 634.5 K (-0.18 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Payment of Exercise | F | 476.42 | 78,376 | 37,339,894 | 635,614 | 714 K to 635.6 K (-10.98 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Buy | M | 30.63 | 150,000 | 4,594,500 | 713,990 | 564 K to 714 K (+26.60 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Payment of Exercise | F | 476.42 | 50,545 | 24,080,649 | 563,990 | 614.5 K to 564 K (-8.22 %) |
| Mar 11 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Buy | M | 30.63 | 96,736 | 2,963,024 | 614,535 | 517.8 K to 614.5 K (+18.68 %) |
| Mar 10 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | M | 33.42 | 2,000 | 66,840 | 0 | |
| Mar 10 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 482.82 | 300 | 144,846 | 9,643 | 9.9 K to 9.6 K (-3.02 %) |
| Mar 10 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 479.21 | 500 | 239,605 | 9,943 | 10.4 K to 9.9 K (-4.79 %) |
| Mar 10 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 476.16 | 200 | 95,232 | 10,443 | 10.6 K to 10.4 K (-1.88 %) |
| Mar 10 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 475.31 | 327 | 155,426 | 10,643 | 11 K to 10.6 K (-2.98 %) |
| Mar 10 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 474.88 | 73 | 34,666 | 10,970 | 11 K to 11 K (-0.66 %) |
| Mar 10 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 471.34 | 100 | 47,134 | 11,043 | 11.1 K to 11 K (-0.90 %) |
| Mar 10 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 470.83 | 200 | 94,166 | 11,143 | 11.3 K to 11.1 K (-1.76 %) |
| Mar 10 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 469.80 | 100 | 46,980 | 11,343 | 11.4 K to 11.3 K (-0.87 %) |
| Mar 10 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 468.14 | 200 | 93,628 | 11,443 | 11.6 K to 11.4 K (-1.72 %) |
| Mar 10 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Buy | M | 33.42 | 2,000 | 66,840 | 11,643 | 9.6 K to 11.6 K (+20.74 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Option Exercise | M | 52.03 | 25,000 | 1,300,750 | 38,079 | |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Option Exercise | M | 52.03 | 25,000 | 1,300,750 | 38,079 | |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 468.56 | 31 | 14,525 | 11,380 | 11.4 K to 11.4 K (-0.27 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 465.42 | 227 | 105,650 | 11,411 | 11.6 K to 11.4 K (-1.95 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 464.14 | 126 | 58,482 | 11,638 | 11.8 K to 11.6 K (-1.07 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 463.10 | 123 | 56,961 | 11,764 | 11.9 K to 11.8 K (-1.03 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 462.15 | 1 | 462 | 11,887 | 11.9 K to 11.9 K (-0.01 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 461.24 | 614 | 283,201 | 11,888 | 12.5 K to 11.9 K (-4.91 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 460.34 | 252 | 116,006 | 12,502 | 12.8 K to 12.5 K (-1.98 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 459.47 | 692 | 317,953 | 12,754 | 13.4 K to 12.8 K (-5.15 %) |